When 22q11.2DS subjects with psychoses need a psychopharmacological treatment, the antipsychotic therapies need to bee carefully chosen, taking into account literature data on efficacy and tolerability. 22q11.2DS subjects seem to have a higher susceptibility to side effects when on antipsychotic therapies than subjects with psychotic disorders (without the 22q11.2DS). In the case report by Kontoangelos et al. 4 , a severe acute dystonia was reported in a subject on a low dosage of Haloperidol and had a good tolerability to quetiapine. In an other very recent paper, Butcher et al., 5 show that 22q11.2DS schizophrenia subjects are at higher risk for severe side effects when on Clozapine, although they had a good clinical response. Further data on clozapine and quetiapine efficacy in 22q11.2DS subjects with relapsing psychoses, are presented by Vorhoeven and Egger. 6 The two atypical antipsychotics in combination with valproic acid, seem more effective than other therapies in their treatment resistant patients' sample
The early-onset Parkinson's disease, 7 of the 22q11DS phenotype in older adults, is a relevant and clinically intriguing data. This phenotype has now been described in multiple case reports, suggesting that dopaminergic disruption in 22q11DS may be relevant to the expression of both psychosis and Parkinson's disease over the life span. These data may suggest a hypothetical explanation of the increased sensitivity to antipsychotics' side effects in 22q11.2DS subjects.
The data currently available on 22q11.2DS, are really promising for further comprehension of that fascinating subject of study which are psychoses and schizophrenia.
